Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 15,485 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 15,485 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $32.62, for a total value of $505,120.70. Following the completion of the transaction, the insider now owns 74,158 shares of the company’s stock, valued at approximately $2,419,033.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.53, for a total value of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.03, for a total value of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total value of $152,075.00.
• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $106,684.76.
• On Monday, September 16th, Catriona Yale sold 2,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.52, for a total value of $68,387.20.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $143,052.00.

Akero Therapeutics Stock Up 4.9 %

Shares of NASDAQ:AKRO opened at $32.33 on Friday. The stock’s 50-day moving average price is $28.32 and its two-hundred day moving average price is $24.78. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12-month low of $12.96 and a 12-month high of $37.00. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -9.48 and a beta of -0.25.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. On average, research analysts forecast that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Hedge Funds Weigh In On Akero Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Akero Therapeutics by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock valued at $92,702,000 after purchasing an additional 584,875 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Akero Therapeutics by 8.1% in the 2nd quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after purchasing an additional 112,426 shares in the last quarter. Capstone Investment Advisors LLC acquired a new position in shares of Akero Therapeutics in the 1st quarter valued at about $2,205,000. Bank of New York Mellon Corp lifted its stake in shares of Akero Therapeutics by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after purchasing an additional 61,988 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Akero Therapeutics by 26.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company’s stock valued at $2,514,000 after purchasing an additional 22,195 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.